Armed T cells (CD20 x CD3)

Armed T cells (CD20 x CD3) is an investigational cell therapy being developed by Lindis Biotech for the treatment of B-cell malignancies, including Non-Hodgkin Lymphoma (NHL), Diffuse Large B-Cell Lymphoma (DLBCL), and Chronic Lymphocytic Leukemia (CLL). The therapy consists of ex vivo expanded T cells that are armed (coated) with a CD20 x CD3 trifunctional bispecific antibody (such as FBTA-05, also known as Bi20 or Lymphomun). This pre-arming approach allows the T cells to directly target and eliminate CD20-positive malignant B cells upon infusion, bypassing the need for systemic administration of the bispecific antibody and potentially reducing systemic toxicities like cytokine release syndrome (CRS). The program is currently in Phase 1 clinical development.

Other names

Bi20-armed T cellsBi-20-armed T cellsBi 20-armed T cellsCD20 x CD3-armed T cellsCD-20 x CD3-armed T cellsCD 20 x CD3-armed T cellsCD20Bi-armed T cellsCD-20Bi-armed T cellsCD 20Bi-armed T cellsFBTA-05-armed T cellsFBTA05-armed T cellsFBTA 05-armed T cellsLymphomun-armed T cells